First Trust Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

First Trust Advisors’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-25,739	Closed	-$382K	–	2621
2021 Q3	$382K	Buy	25,739 +1,114	+5%	+$17.8K	﹤0.01%	2337
2021 Q2	$492K	Sell	24,625 -2,541,393	-99%	-$50.4M	﹤0.01%	2285
2021 Q1	$59.2M	Buy	2,566,018 +609,716	+31%	+$17M	0.07%	391
2020 Q4	$48.3M	Buy	1,956,302 +447,294	+30%	+$14.8M	0.06%	434
2020 Q3	$62.6M	Buy	1,509,008 +700,492	+87%	+$32.2M	0.1%	265
2020 Q2	$38.7M	Buy	808,516 +253,076	+46%	+$19.6M	0.07%	400
2020 Q1	$35M	Sell	555,440 -224,109	-29%	-$20.1M	0.08%	399
2019 Q4	$96.6M	Sell	779,549 -103,036	-12%	-$9.22M	0.17%	134
2019 Q3	$58.6M	Sell	882,585 -210,523	-19%	-$14.1M	0.11%	245
2019 Q2	$87M	Buy	1,093,108 +191,132	+21%	+$17.1M	0.16%	154
2019 Q1	$101M	Sell	901,976 -79,507	-8%	-$8.69M	0.2%	120
2018 Q4	$98.9M	Sell	981,483 -110,836	-10%	-$11.5M	0.23%	73
2018 Q3	$138M	Buy	1,092,319 +251,735	+30%	+$26.6M	0.26%	66
2018 Q2	$70.5M	Buy	840,584 +22,310	+3%	+$1.63M	0.15%	138
2018 Q1	$50.3M	Buy	818,274 +212,820	+35%	+$12.8M	0.12%	191
2017 Q4	$35.4M	Buy	605,454 +304,999	+102%	+$19.2M	0.08%	304
2017 Q3	$17.4M	Buy	300,455 +13,044	+5%	+$1.4M	0.04%	563
2017 Q2	$34.8M	Buy	287,411 +41,856	+17%	+$4.85M	0.09%	255
2017 Q1	$27.8M	Sell	245,555 -35,187	-13%	-$4.11M	0.08%	324
2016 Q4	$30.5M	Buy	280,742 +98,119	+54%	+$11.7M	0.09%	274
2016 Q3	$30.1M	Sell	182,623 -9,262	-5%	-$1.46M	0.09%	277
2016 Q2	$27.4M	Sell	191,885 -57,492	-23%	-$8.38M	0.09%	288
2016 Q1	$32M	Sell	249,377 -339,489	-58%	-$40.1M	0.1%	241
2015 Q4	$87.9M	Buy	588,866 +124,493	+27%	+$21.1M	0.23%	95
2015 Q3	$77M	Sell	464,373 -23,086	-5%	-$5.08M	0.22%	96
2015 Q2	$118M	Sell	487,459 -150,815	-24%	-$40.2M	0.31%	63
2015 Q1	$180M	Buy	638,274 +361,089	+130%	+$78.2M	0.53%	14
2014 Q4	$43.2M	Buy	277,185 +265,900	+2,356%	+$49.1M	0.15%	162
2014 Q3	$2.67M	Buy	+11,285	New	+$2.88M	0.01%	1223

Other funds holding ICPT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

First Trust Advisors's ICPT Position: Q4 2021 in Review

First Trust Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2021, closing a stake of 25,739 shares — an estimated $382K sold.

First Trust Advisors first reported a position in ICPT in Q3 2014 and held it in 29 quarters. The position peaked at $180M in Q1 2015. 147 funds tracked by Wall St. Rank hold ICPT as of Q4 2021.

First Trust Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
First Trust Advisors sold 25,739 Intercept Pharmaceuticals, Inc. shares in Q4 2021, an estimated $382K.
First Trust Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2014 and held it in 29 quarters.
First Trust Advisors's Intercept Pharmaceuticals, Inc. position peaked at $180M in Q1 2015.
147 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2021.

Based on First Trust Advisors's 13F filing for Q4 2021, filed 8 Feb 2022.